Thursday, May 26, 2016 8:52:32 PM
Here's some of the CS notes from Mylans IPR challenge:
IPR Hearing Generally In-Line With Expectations
¦ Bottom Line: Today's hearing of Inter Partes Review (IPR) petitions on Teva's 40 mg/ml formulation played out close to what we (and we believe Consensus) was expecting. As we mentioned in our initiation note (link), we believe it will be difficult for Teva to be successful in protecting these three patents and we model generic entry in late 2018, once appeal processes are done, but we also note that this is just one step in a three-step process that competitors would need to win in order to safely launch generic versions of the 40 mg/ml formulation.
¦ IPR hearing fair and respectful, but outcome likely in petitioners' favor. • Our expert commented the three judges who listened to both parties appearedengaged and did not express any apparent conviction either way. The petitioners argued that a 40mg/ml three times weekly was obvious based on data for once daily and once every other day administration, suggesting the new dosing regimen was obvious based on prior experience. TEVA, on the other hand, argued prior experience with 40mg/ml every other day does not suggest that lowering that dosage to three times weekly would lead to equal efficacy. We note a fourth patent that TEVA has on the formulation based on improved tolerability with three times weekly dosing was not part of the IPR hearing and provides another layer of protection for the product.
¦ PTAB decision expected in August. The decision on the IPR hearing is expected in August, and if Teva loses it has a right to appeal, extending out the process an additional 12-15 months. Petitioner has also filed a Post GrantReview (PGR) on the 4th patent and we are expecting Teva to submit their response to the PGR by May 24th. The decision on instituting the PGR is also expected by the end of August. In addition, Teva is involved in a District Court case for which it has filed patent infringement lawsuits against multiple parties including petitioner, Dr. Reddy's and Sandoz/Momenta. Given the length of time it will take all processes (including any appeals) we model entry of generic versions of Copaxone 40mg/ml in late 2018
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM